跳至主要内容
临床试验/NCT00293462
NCT00293462已完成3 期

Management of Mucositis With GM-CSF (Sargramostim) Mouthwash Study Protocol

Marilyn Dodd2 个研究点 分布在 1 个国家目标入组 91 人开始时间: 2005年6月7日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
Marilyn Dodd
入组人数
91
试验地点
2
主要终点
Comparison of Number of Participants With Grade 1 or 2 Oral Mucositis (GM-CSF and SS Groups Only)

研究概览

简要总结

GM-CSF may protect normal cells from the side effects, such as mucositis, of radiation therapy and may help damaged tissue heal faster after radiation therapy. This randomized clinical trial is studying how well GM-CSF works in preventing and treating mucositis in patients who are undergoing radiation therapy for head and neck cancer.

详细描述

OBJECTIVES:

Primary

  • Compare the incidence of radiotherapy (RT)-induced oral mucositis of any grade, using the Radiation Therapy Oncology Group Acute Radiation Morbidity Scoring Criteria (RTOG ARMSC)-Mucous Membrane, in patients treated with 1 of 2 mouthwashes (sargramostim [GM-CSF] or salt and soda). (prevention portion of the study)
  • Compare the effectiveness of the 2 mouthwashes in treating oral mucositis as defined by the incidence of RTOG ARMSC-Mucous Membrane grade 3 and 4 mucositis in patients in 1 of 3 groups (salt and soda, continuing GM-CSF, or new GM-CSF). (treatment portion of the study)

Secondary

  • Compare the effectiveness of the 2 mouthwashes in preventing RT-induced oral mucositis by the following direct indices:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Supportive Care
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Comparison of Number of Participants With Grade 1 or 2 Oral Mucositis (GM-CSF and SS Groups Only)

时间窗: From baseline to onset of mucositis, approximately 16 days

The number of participants with recorded grade 1 (mild; Irritation, may experience slight pain, not requiring analgesic) or grade 2 (moderate; Patchy mucositis that may produce inflammatory serosanguinitis discharge; may experience moderate pain requiring analgesia) oral mucositis using the Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria Oral Mucosa Assessment Scale at baseline and during radiotherapy will be recorded. The RTOG grading is reliant on a clinician's ability to judge the anatomical changes associated with oral mucositis (size and characteristics of ulceration), with symptoms ranging from Grade 0 (no symptoms) to Grade 4 (Ulceration, hemorrhage, or necrosis). A comparison of incidence in the GM-CSF Group (GG) and Arm II: Salt \& Soda Group (SS) will be reported.

Comparison of the Mean Number of Days for Mucositis to Heal Across by Group

时间窗: From onset of mucositis to healing of mucositis, approximately 80 days

The mean number of days for mucositis to heal will be used to evaluate the effectiveness of the two mouthwashes in treating oral mucositis as defined by the incidence of Radiation Therapy Oncology Group Acute Radiation Morbidity Scoring.

次要结局

  • Comparison of Combined Mean Score on the Pain Questionnaire by Group(Up to 3 months)
  • Comparison of the Combined Mean Score on the Overall Quality of Life Questionnaires by Group(Up to 3 months)
  • Comparison of Combined Mean Score on the Karnofsky Performance Status Scale (KPS) by Group(Up to 3 months)

研究者

发起方
Marilyn Dodd
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Marilyn Dodd

Principal Investigator

University of California, San Francisco

研究点 (2)

Loading locations...

相似试验